LONDON: Remdesivir and Hydroxychloroquine (HCQ) do not show antivirus activity in hospitalized patients with Covid-19 in Norway, according to a study published on Tuesday.
While HCQ is used to prevent or treat malaria, remedies for sale as antivirus drugs.
Researchers from the University of Oslo and colleagues randomly assigned 181 patients who were hospitalized in 23 hospitals in Norway to receive rempasses, HCQ, or maintenance standards.
This study, published in the journal Annals of Internal Medicine, evaluates the effects of two drugs in all causes, hospital deaths, respiratory failure rates and inflammation, and virus permits in oropharynx.
The ‘Nor-Solidarity’ study, independently controlled trial, add-on, random to the World Health Organization Solidarity Court (WHO), found that rempassivir or HCQ affected the permit virus in Covid-19 patients.
The WHO solidarity trial does not show the effect of remediesivir or HCQ about mortality but does not assess the antivirus effect of these drugs.
Recent studies did not find significant differences between treatment groups against mortality during hospitalization.
The researchers also found that remdesivir and HCQ did not affect the level of respiratory failure or inflammation.
There was a significant decrease in the load of SARS-COV-2 in oropharynx during the first week in all treatment groups, with a similar decline in a 10-day viral load.
The lack of antiviral effects with remedies and HCQ remains consistent even though the patient’s age, the duration of symptoms, the degree of viral load, and the existence of antibodies to SARS-COV-2.
The researchers noted that overall death in nor-solidarity was lower than in the Who-Solidarity trial.
This could be caused by the initial locking policy in Norway during the initial phase of the pandemic, reducing pressure on hospitals and health care systems, the researchers said.
Norway also has a lower level of comorbid conditions such as diabetes and chronic heart disease, they said.
Based on their findings, the researchers questioned the potential of antivirus remdesivir and HCQ.